Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.70 |
| ▸ | DRD2 | P14416 | 8/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602191 | 0.87 | HRH4 (0.75) | DRD3DRD2HRH4HRH3ACHE | |
| SCHEMBL603847 | 0.85 | HRH4 (0.58) | DRD3DRD2HRH4HRH3 | |
| SCHEMBL601512 | 0.82 | DRD3 (1.00) | DRD3DRD2HRH4ACHE | |
| SCHEMBL603781 | 0.82 | DRD3 (0.78) | DRD3DRD2HRH4ACHE | |
| SCHEMBL3337825 | 0.78 | PDE2A (0.66) | — | |
| SCHEMBL9006364 | 0.77 | DRD3 (1.00) | DRD3DRD2ACHE | |
| SCHEMBL10745905 | 0.77 | AMY1A (0.53) | — | |
| SCHEMBL602147 | 0.77 | HRH4 (0.71) | DRD3DRD2HRH4HRH3ACHE | |
| SCHEMBL604153 | 0.76 | HRH4 (0.75) | DRD3DRD2HRH4ACHE | |
| SCHEMBL601426 | 0.76 | HRH4 (0.76) | DRD3DRD2HRH4HRH3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | DRD3 805/4885DRD2 683/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.